From mice to men: GEMMs as trial patients for new NSCLC therapies

Seminars in Cell and Developmental Biology

Volumn 27, Issue , 2014, Pages 118-127

  Hayes, Sarah A ^a,b   Hudson, Amanda L ^a,b   Clarke, Stephen J ^a,b   Molloy, Mark P ^c   Howell, Viive M ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

Author keywords

AdCre; ALK; ANGPTL3; Ccsp; EGFR; EML4 ALK; GEMMs; Genetically engineered mouse model (GEMM); HSP; IN; Kras; LentiCre; Lung cancer; Mouse model; NSCLC; OS; PFS; SCC; SFTPB; SFTPD; SPC; TK; TKI; WFDC2

Indexed keywords

AFATINIB; BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DACTOLISIB; DOCETAXEL; ERLOTINIB; GELDANAMYCIN; NAVITOCLAX; PEMETREXED; SELUMETINIB; SUNITINIB; TOFACITINIB; TUMOR MARKER; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER THERAPY; CELL THERAPY; DRUG EFFICACY; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; REVIEW; SOCIOECONOMICS; ANIMAL; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; DRUG SCREENING; GENETIC ENGINEERING; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; PERSONALIZED MEDICINE; TRANSGENIC MOUSE;

ANIMALIA; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENETIC ENGINEERING; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84901259835     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2014.04.002     Document Type: Review

References (78)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1999. CA-Cancer J Clin 1999, 49:8-31.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA-Cancer J Clin 2005, 55:74-108.
3. World Health Organisation World Cancer Report 2014 2014, International Agency for Research on Cancer, Lyon, France. B.W. Stewart, C.P. Wild (Eds.).
4. Imielinski M., Berger Alice H., Hammerman Peter S., Hernandez B., Pugh Trevor J., Hodis E., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150:1107-1120.
5. Reungwetwattana T., Dy G.K. Targeted therapies in development for non-small cell lung cancer. J Carcinog 2013, 12:22.
6. Dempke W., Suto T., Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer 2010, 67:257-274.
7. Rossi A., Maione P., Palazzolo G., Sacco P.C., Ferrara M.L., Falanga M., et al. New targeted therapies and small-cell lung cancer. Clin Lung Cancer 2008, 9:271-279.
8. Ji H., Li D., Chen L., Shimamura T., Kobayashi S., McNamara K., et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006, 9:485-495.
9. Burdett S., Stephens R., Stewart L., Tierney J., Auperin A., Le Chevalier T., et al. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials-NSCLC meta-analyses collaborative group. J Clin Oncol 2008, 26(October (28)):4617-4625.
10. Suggitt M., Bibby M.C. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 2005, 11:971-981.
11. Khalid W., Liu P. Cancer mouse models: past, present and future. Sem Cell Dev Biol 2014, 27:54-60.
12. Govindan R., Ding L., Griffith M., Subramanian J., Dees Nathan D., Kanchi Krishna L., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012, 150:1121-1134.
13. Ma C., Wei S., Song Y. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 2011, 3:10-18.
14. Katayama R., Khan T.M., Benes C., Lifshits E., Ebi H., Rivera V.M., et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011, 108:7535-7540.
15. Zhang S., Wang F., Keats J., Zhu X., Ning Y., Wardwell S.D., et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des 2011, 78:999-1005.
16. Chen Z., Cheng K., Walton Z., Wang Y., Ebi H., Shimamura T., et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012, 483:613-617.
17. Malaney P., Nicosia S.V., Davé V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett 2014, 344:1-12.
18. Nardella C., Lunardi A., Patnaik A., Cantley L.C., Pandolfi P.P. The APL paradigm and the co-clinical trial project. Cancer Discov 2011, 1:108-116.
19. Howell V.M., Jones J.M., Bergren S.K., Li L., Billi A.C., Avenarius M.R., et al. Evidence for a direct role of the disease modifier SCNM1 in splicing. Hum Mol Genet 2007, 16:2506-2516.
20. Threadgill D.W., Churchill G.A. Ten years of the collaborative cross. Genetics 2012, 190:291-294.
21. Crowley J.J., Kim Y., Lenarcic A.B., Quackenbush C.R., Barrick C.J., Adkins D.E., et al. Genetics of adverse reactions to haloperidol in a mouse diallel: a drug-placebo experiment and bayesian causal analysis. Genetics 2014, 196:321-347.
22. Hasegawa Y., Kawaguchi T., Kubo A., Ando M., Shiraishi J., Isa S.-i., et al. Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in Phase II and III clinical trials. J Thorac Oncol 2011, 6:1881-1888.
23. Zhou W., Christiani D.C. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin Clin Oncol 2011, 30:287-292.
24. Szabova L., Yin C., Bupp S., Guerin T.M., Schlomer J.J., Householder D.B., et al. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res 2012, 72:4141-4153.
25. Sutherland K.D., Song J.-Y., Kwon M.C., Proost N., Zevenhoven J., Berns A. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc Natl Acad Sci USA 2014, 28. [published online before print February]. 10.1073/pnas.1319963111.
26. de Seranno S., Meuwissen R. Progress and applications of mouse models for human lung cancer. Eur Respir J 2010, 35:426-443.
27. Kwon M.-C., Berns A. Mouse models for lung cancer. Mol Oncol 2013, 7:165-777.
28. Berge E.M., Doebele R.C. Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Sem Oncol 2014, 41:110-125.
29. Stinchcombe T.E., Der C.J. Are all KRAS mutations created equal. Lancet Oncol 2011, 12:717-718.
30. The COSMIC (Catalogue of Somatic Mutations in Cancer) database. Version 68 (2004). [accessed 21.02.14]. http://www.sanger.ac.uk/cosmic.
31. Ihle N.T., Byers L.A., Kim E.S., Saintigny P., Lee J.J., Blumenschein G.R., et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012, 104:228-239.
32. Singh M., Lima A., Molina R., Hamilton P., Clermont A.C., Devasthali V., et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 2010, 28:585-593.
33. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14:1351-1356.
34. LoRusso P., Shapiro G., Pandya S.S., Kwak E.L., Jones C., Belvin M., et al. A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. J Clin Oncol 2012, ASCO Annual Meeting.
35. Speranza G., Kinders R.J., Khin S., Weil M.K., Do K.T., Horneffer Y., et al. Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC). J Clin Oncol 2012, ASCO Annual Meeting.
36. Jänne P.A., Shaw A.T., Pereira J.R., Jeannin G., Vansteenkiste J., Barrios C., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013, 14:38-47.
37. Ji H., Ramsey M.R., Hayes D.N., Fan C., McNamara K., Kozlowski P., et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007, 448:807-810.
38. Corcoran Ryan B., Cheng Katherine A., Hata Aaron N., Faber Anthony C., Ebi H., Coffee Erin M., et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013, 23:121-128.
39. National Cancer Institute (NCI); Dana-Farber Cancer Institute. Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors. NLM Identifier: : In ClinicalTrials.gov [Internet]; 2014-[cited March 2014]. ctgov:NCT02079740.
40. Socinski M.A., Novello S., Brahmer J.R., Rosell R., Sanchez J.M., Belani C.P., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:650-656.
41. Gandhi L., McNamara K.L., Li D., Borgman C.L., McDermott U., Brandstetter K.A., et al. Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. Cancer Prev Res 2009, 2:330-337.
42. Metro G., Crinò L. The LUX-lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Rev Anticancer Ther 2011, 11:673-682.
43. Regales L., Balak M.N., Gong Y., Politi K., Sawai A., Le C., et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE 2007, 2:e810.
44. Regales L., Gong Y., Shen R., de Stanchina E., Vivanco I., Goel A., et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009, 119:3000-3010.
45. Kirkpatrick P., Graham J., Muhsin M. Cetuximab Nat Rev Drug Discov 2004, 3:549-550.
46. Boehringer Ingelheim Trial of BIBW 2992 (Afatinib)+Cetuximab in Non-Small Cell Lung Cancer. NLM Identifier: : In: ClinicalTrials.gov [Internet]; 2010-[cited March 2014]. ctgov:NCT01090011.
47. Schoeberl B., Faber A.C., Li D., Liang M.-C., Crosby K., Onsum M., et al. An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation. Cancer Res 2010, 70:2485-2494.
48. Merrimack Pharmaceuticals; Sanofi. A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers. NLM Identifier: : In: ClinicalTrials.gov [Internet]; 2011-[cited March 2014]. ctgov:NCT01451632.
49. Faber A.C., Li D., Song Y., Liang M.-C., Yeap B.Y., Bronson R.T., et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 2009, 106:19503-19508.
50. Zhou W., Ercan D., Chen L., Yun C.-H., Li D., Capelletti M., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
51. Perez C.A., Velez M., Raez L.E., Santos E.S. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation. Lung Cancer 2014, [PII: S0169-5002(14)00064-6, in press; corrected proof]. 10.1016/j.lungcan.2014.02.001.
52. Kwak E.L., Bang Y.-J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
53. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
54. Horn L., Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009, 27:4232-4235.
55. Mori M., Ueno Y., Konagai S., Fushiki H., Shimada I., Kondoh Y., et al. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. Mol Cancer Ther 2014, 13:329-340.
56. Sasaki T., Okuda K., Zheng W., Butrynski J., Capelletti M., Wang L., et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010, 70:10038-10043.
57. Galvani A., Ardini E. ALK inhibitors, a pharmaceutical perspective. Front Oncol 2012, 2.
58. Shaw A.T., Kim D.-W., Nakagawa K., Seto T., Crinó L., Ahn M.-J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
59. Chen Z., Akbay E., Mikse O., Tupper T., Cheng K., Wang Y., et al. Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res 2014, 20:1204-1211.
60. Chen Z., Sasaki T., Tan X., Carretero J., Shimamura T., Li D., et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 2010, 70:9827-9836.
61. Sequist L.V., Gettinger S., Senzer N.N., Martins R.G., Jänne P.A., Lilenbaum R., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010, 28:4953-4960.
62. Soda M., Takada S., Takeuchi K., Choi Y.L., Enomoto M., Ueno T., et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008, 105:19893-19897.
63. Astellas Pharma Inc. Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma). NLM Identifier: : In: ClinicalTrials.gov [Internet]; 2011-[cited March 2014]. ctgov:NCT01284192.
64. Hanash S.M., Baik C.S., Kallioniemi O. Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 2011, 8:142-150.
65. Taguchi A., Politi K., Pitteri S.J., Lockwood W.W., Faça V.M., Kelly-Spratt K., et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011, 20:289-299.
66. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
67. Oliver T.G., Mercer K.L., Sayles L.C., Burke J.R., Mendus D., Lovejoy K.S., et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 2010, 24:837-852.
68. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001, 15:3243-3248.
69. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001, 410:1111-1116.
70. Lopez-Chavez A., Young T., Fages S., Leon L., Schiller J.H., Dowlati A., et al. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the eastern cooperative oncology group 4599 study: results of an exploratory analysis. J Thorac Oncol 2012, 7:1707-1712.
71. Johnson B.E., Kabbinavar F., Fehrenbacher L., Hainsworth J., Kasubhai S., Kressel B., et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2013, 31:3926-3934.
72. Perez B.A., Ghafoori A.P., Lee C.-L., Johnston S.M., Li Y.I., Moroshek J.G., et al. Assessing the radiation response of lung cancer with different gene mutations using genetically engineered mice. Front Oncol 2013, 3.
73. Winslow M.M., Dayton T.L., Verhaak R.G., Kim-Kiselak C., Snyder E.L., Feldser D.M., et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 2011, 473:101-104.
74. Perez B.A., Ghafoori A.P., Lee C.L., Johnston S.M., Li Y., Moroshek J.G., et al. Assessing the radiation response of lung cancer with different gene mutations using genetically engineered mice. Front Oncol 2013, 3:72.
75. Jackson E.L., Olive K.P., Tuveson D.A., Bronson R., Crowley D., Brown M., et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005, 65:10280-10288.
76. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001, 15:3249-3262.
77. Politi K., Zakowski M.F., Fan P.D., Schonfeld E.A., Pao W., Varmus H.E. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006, 20:1496-1510.
78. Williams T.I., Toups K.L., Saggese D.A., Kalli K.R., Cliby W.A., Muddiman D.C. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J Proteome Res 2007, 6:2936-2962.